Gilead (GILD) Earns Buy Rating at Truist as HIV Franchise Continues to Deliver

Core Insights - Gilead Sciences, Inc. (NASDAQ:GILD) is recognized as one of the 15 Best Boring Dividend Stocks to Buy, indicating a stable investment opportunity in the dividend space [1] - Truist initiated coverage of Gilead with a Buy rating and a price target of $140, citing the strength of its HIV portfolio and promising next-generation programs as key factors for a positive long-term outlook [2] - The company's HIV treatment Biktarvy generated $3.7 billion in sales, reflecting a 6% increase year-over-year, while Descovy's revenue rose 20% to $701 million, showcasing robust performance in its core business [3] - Gilead's liver disease treatments also contributed to growth, with sales increasing 12% year-over-year to $819 million, supporting the company's diversification strategy [4] Business Performance - Gilead's underlying business remains solid, with a focus on broadening its portfolio beyond the HIV segment to reduce dependence on it over time [4] - The ongoing strength of the HIV franchise and advancements in oncology efforts are viewed as significant drivers for future growth [2][3]